Tavo Biotherapeutics is developing innovative treatments to address critical unmet needs in ophthalmology. TAV-001 engages two novel targets that represent fundamental mechanisms underlying the pathology of glaucoma-related neurodegeneration. In pre-clinical studies, TAV-001 has shown signals of neuroprotection as well as substantial reduction in intraocular pressure, suggesting that it could represent the first disease-modifying pharmaceutical therapy for these patients. TAV-001 is expected to enter a Phase 1 clinical trial in glaucoma patients in 2025. TAV-002 represents a potential first-in-class treatment for retinal disease, including diabetic retinopathy, diabetic macular edema, and both wet and dry age-related macular degeneration. Tavo has initiated IND-enabling activities for this program.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Critical Unmet Needs In Ophthalmology
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://tavobio.com
- Keywords
- OculoTherapy.
Tavo Biotherapeutics Questions
Tavo Biotherapeutics's website is http://tavobio.com
Tavo Biotherapeutics's LinkedIn profile is https://www.linkedin.com/company/tavo-bio
Tavo Biotherapeutics has
9 employees.
View email and phone details for 9
employees at Tavo Biotherapeutics.
Tavo Biotherapeutics's industry is
Biotechnology Research
Tavo Biotherapeutics's top competitors are
Unity Biotechnology,
Tarsus Pharmaceuticals, Inc.,
Oculotherapy,
Apellis Pharmaceuticals,
Peak Biosolutions,
Osheru - Ziplyft,
Trexbio,
Firecyte Therapeutics,
Peripherex,
Nulids.
Tavo Biotherapeutics's categories are Biotechnology Research
Tavo Biotherapeutics's founding year is 2024
